Regeneron Pharmaceuticals Other intangible assets—net increased by 2.3% to $1.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.3%, from $1.17B to $1.29B. Over 4 years (FY 2021 to FY 2025), Other intangible assets—net shows an upward trend with a 270.1% CAGR.
An increase typically follows acquisitions, while a steady decrease reflects ongoing amortization of existing intangible assets.
This represents the net book value of identifiable non-physical assets such as acquired technology, patents, customer li...
Standard for companies that grow through M&A, often labeled 'Intangible assets, net'.
non_current_assets_intangible_assets_net_excluding_goodwill| Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.70M | $804.10M | $915.50M | $928.70M | $953.00M | $1.02B | $1.04B | $1.06B | $1.10B | $1.12B | $1.15B | $1.17B | $1.35B | $1.38B | $1.26B | $1.29B |
| QoQ Change | — | >999% | +13.9% | +1.4% | +2.6% | +6.7% | +2.1% | +1.9% | +4.1% | +1.6% | +2.5% | +1.6% | +15.8% | +2.2% | -8.9% | +2.3% |
| YoY Change | — | — | >999% | — | — | +26.5% | +13.4% | +14.0% | +15.7% | +10.1% | +10.6% | +10.2% | +22.6% | +23.3% | +9.5% | +10.3% |